Suppr超能文献

5-HT2和5-HT4受体拮抗剂对小鼠明暗试验中药物诱导的去抑制作用的影响。

The influence of 5-HT2 and 5-HT4 receptor antagonists to modify drug induced disinhibitory effects in the mouse light/dark test.

作者信息

Costall B, Naylor R J

机构信息

Postgraduate Studies in Pharmacology, School of Pharmacy, University of Bradford, West Yorkshire.

出版信息

Br J Pharmacol. 1997 Nov;122(6):1105-18. doi: 10.1038/sj.bjp.0701513.

Abstract
  1. The ability of 5-HT2 and 5-HT4 receptor antagonists to modify the disinhibitory profile of diazepam and other agents was investigated in male BKW mice in the light/dark test box. 2. The 5-HT2A/2B/2C receptor antagonists ritanserin, MDL11939 and RP62203 and also methysergide, which failed to modify mouse behaviour when administered alone, caused dose-related enhancements (4 to 8 fold) in the potency of diazepam to disinhibit behavioural responding to the aversive situation of the test box. 3. Ritanserin was shown to enhance the disinhibitory potency of other benzodiazepines, chlordiazepoxide (4 fold), temazepam (10 fold) and lorazepam (10 fold), the 5-HT1A receptor ligands, 8-OH-DPAT (25 fold), buspirone (100 fold) and lesopitron (500 fold), the 5-HT3 receptor antagonists, ondansetron (100 fold) R(+)-zacopride (100 fold) and S(-)-zacopride (greater than a 1000 fold), the substituted benzamides, sulpiride (10 fold) and tiapride (5 to 10 fold) and the cholecystokinin (CCK)A receptor antagonist, devazepide (100 fold). It also reduced the onset of action of disinhibition following treatment with the 5-HT synthesis inhibitor parachlorophenylalanine. Ritanserin failed to enhance the disinhibitory effects of the CCKB receptor antagonist CI-988, the angiotensin AT1 receptor antagonist losarten or the angiotensin converting enzyme inhibitor ceranapril. 4. The 5-HT4 receptor antagonists SDZ205-557, GR113808 and SB204070 caused dose-related reductions in the disinhibitory effect of diazepam, returning values to those shown in vehicle treated controls. The antagonists failed to modify mouse behaviour when administered alone. 5. GR113808 was also shown to cause a dose-related antagonism of the disinhibitory effects of chlordiazepoxide, lorazepam, 8-OH-DPAT, buspirone, lesopitron, ondansetron, R(+)-zacopride, sulpiride, tiapride, devazepide, CI-988, losarten, ceranapril and parachlorophenylalanine. 6. It was concluded that in BKW mice (a) the failure of 5-HT2 and 5-HT4 receptor antagonists when administered alone to modify behaviour in the light/dark test indicates an absence of an endogenous 5-HT tone at the 5-HT2 and 5-HT4 receptors and (b) the enhancement by the 5-HT2 receptor antagonists and attenuation by the 5-HT4 receptor antagonists of drug-induced disinhibition indicates a plurality of 5-HT receptor involvement in the mediation of drug-induced disinhibitory profiles in the mouse.
摘要
  1. 在明暗实验箱中,对雄性BKW小鼠研究了5-HT2和5-HT4受体拮抗剂改变地西泮及其他药物去抑制作用特征的能力。2. 5-HT2A/2B/2C受体拮抗剂利坦色林、MDL11939和RP62203以及单独给药时未改变小鼠行为的美西麦角,导致地西泮抑制对实验箱厌恶情境的行为反应的效力出现剂量相关增强(4至8倍)。3. 利坦色林被证明可增强其他苯二氮䓬类药物的去抑制效力,如氯氮䓬(4倍)、替马西泮(10倍)和劳拉西泮(10倍),5-HT1A受体配体8-OH-DPAT(25倍)、丁螺环酮(100倍)和来索吡隆(500倍),5-HT3受体拮抗剂昂丹司琼(100倍)、R(+)-扎考必利(100倍)和S(-)-扎考必利(大于1000倍),取代苯甲酰胺类药物舒必利(10倍)和硫必利(5至10倍)以及胆囊收缩素(CCK)A受体拮抗剂地伐西匹(100倍)。它还缩短了5-HT合成抑制剂对氯苯丙氨酸治疗后去抑制作用的起效时间。利坦色林未能增强CCKB受体拮抗剂CI-988、血管紧张素AT1受体拮抗剂氯沙坦或血管紧张素转换酶抑制剂西拉普利的去抑制作用。4. 5-HT4受体拮抗剂SDZ205-557、GR113808和SB204070导致地西泮去抑制作用出现剂量相关降低,使数值恢复到溶剂处理对照组所示水平。这些拮抗剂单独给药时未改变小鼠行为。5. GR113808还被证明可对氯氮䓬、劳拉西泮、8-OH-DPAT、丁螺环酮、来索吡隆、昂丹司琼、R(+)-扎考必利、舒必利、硫必利、地伐西匹、CI-988、氯沙坦、西拉普利和对氯苯丙氨酸的去抑制作用产生剂量相关拮抗。6. 得出的结论是,在BKW小鼠中:(a) 5-HT2和5-HT4受体拮抗剂单独给药时未能改变明暗实验中的行为,表明5-HT2和5-HT4受体不存在内源性5-HT张力;(b) 5-HT2受体拮抗剂增强而5-HT4受体拮抗剂减弱药物诱导的去抑制作用,表明多种5-HT受体参与介导小鼠药物诱导的去抑制作用特征。

相似文献

9
The pharmacology of the 5-HT4 receptor.5-羟色胺4受体的药理学
Int Clin Psychopharmacol. 1993 Nov;8 Suppl 2:11-8. doi: 10.1097/00004850-199311002-00002.

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验